Fractyl Health, Inc. (NASDAQ:GUTS) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Fractyl Health, Inc. (NASDAQ:GUTS) has been assigned a consensus recommendation of “Moderate Buy” from the five analysts that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $7.40.

A number of analysts recently weighed in on GUTS shares. Canaccord Genuity Group reaffirmed a “buy” rating and set a $8.00 price target on shares of Fractyl Health in a research report on Friday, December 19th. HC Wainwright reissued a “buy” rating and issued a $8.00 price objective on shares of Fractyl Health in a research report on Tuesday, December 2nd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Fractyl Health in a research note on Monday, December 29th.

Hedge Funds Weigh In On Fractyl Health

Institutional investors and hedge funds have recently bought and sold shares of the stock. Catalyst Funds Management Pty Ltd acquired a new stake in Fractyl Health in the second quarter valued at approximately $26,000. Bank of America Corp DE lifted its position in shares of Fractyl Health by 23.5% during the third quarter. Bank of America Corp DE now owns 88,634 shares of the company’s stock worth $141,000 after purchasing an additional 16,856 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of Fractyl Health in the second quarter valued at $31,000. FNY Investment Advisers LLC acquired a new stake in Fractyl Health during the 3rd quarter valued at $31,000. Finally, Scientech Research LLC purchased a new stake in Fractyl Health during the 3rd quarter worth $49,000.

Fractyl Health Stock Performance

GUTS opened at $2.00 on Friday. Fractyl Health has a 1 year low of $0.82 and a 1 year high of $3.03. The firm has a 50 day moving average price of $1.80 and a 200 day moving average price of $1.50. The company has a market cap of $274.08 million, a PE ratio of -0.87 and a beta of 1.62.

Fractyl Health (NASDAQ:GUTS) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.01). On average, sell-side analysts predict that Fractyl Health will post -1.61 earnings per share for the current year.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.